Posaconazole for the prophylaxis of invasive aspergillosis in acute myeloid leukemia: Is it still useful outside the clinical trial setting?

BACKGROUND: Posaconazole prophylaxis during remission induction chemotherapy not only decreases the incidence of invasive aspergillosis (IA) but also improves the overall survival rate among patients with acute myeloid leukemia (AML). However, it remains debatable whether this result applies to pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Tsung-Chih, Wang, Ren Ching, Lin, Yu-Hui, Chang, Kuang-Hsi, Hung, Li-Ya, Teng, Chieh-Lin Jerry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607783/
https://www.ncbi.nlm.nih.gov/pubmed/33194163
http://dx.doi.org/10.1177/2040620720965846

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607783/
https://www.ncbi.nlm.nih.gov/pubmed/33194163
http://dx.doi.org/10.1177/2040620720965846

Ejemplares similares